Double-blind, randomized, controlled clinical trial of norfloxacin for cholera | Zendy

Sujit Bhattacharya | Zendy; M.K. Bhattacharya | Zendy; P Dutta | Zendy; Deblina Dutta | Zendy; S.P. De | Zendy; Sohini Sikdar | Zendy; Anirban Maitra | Zendy; Adrish Dutta | Zendy; Sangita Pal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Double-blind, randomized, controlled clinical trial of norfloxacin for cholera

Author(s) -

Sujit Bhattacharya,

M.K. Bhattacharya,

P Dutta,

Deblina Dutta,

S.P. De,

Sohini Sikdar,

Anirban Maitra,

Adrish Dutta,

Sangita Pal

Publication year - 1990

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.34.5.939

Subject(s) - norfloxacin , placebo , cholera , diarrhea , medicine , vibrio cholerae , randomized controlled trial , trimethoprim , double blind , sulfamethoxazole , gastroenterology , antibiotics , microbiology and biotechnology , virology , biology , ciprofloxacin , genetics , alternative medicine , pathology , bacteria

In a double-blind, randomized clinical trial with 78 adults with acute watery diarrhea and severe dehydration, 37 subjects were positive for Vibrio cholerae. In conjunction with rehydration therapy, 13 patients received norfloxacin, 12 received trimethoprim-sulfamethoxazole (TMP-SMX), and 12 received a placebo. Norfloxacin was superior to TMP-SMX and to the placebo in reducing stool output, duration of diarrhea, fluid requirements, and vibrio excretion. TMP-SMX was no better than the placebo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research